Serveur d'exploration Santé et pratique musicale

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Appropriateness Criteria for Active Surveillance of Prostate Cancer.

Identifieur interne : 000A83 ( Main/Exploration ); précédent : 000A82; suivant : 000A84

Appropriateness Criteria for Active Surveillance of Prostate Cancer.

Auteurs : Michael L. Cher [États-Unis] ; Apoorv Dhir [États-Unis] ; Gregory B. Auffenberg [États-Unis] ; Susan Linsell [États-Unis] ; Yuqing Gao [États-Unis] ; Bradley Rosenberg [États-Unis] ; S Mohammad Jafri [États-Unis] ; Laurence Klotz [Canada] ; David C. Miller [États-Unis] ; Khurshid R. Ghani [États-Unis] ; Steven J. Bernstein [États-Unis] ; James E. Montie [États-Unis] ; Brian R. Lane [États-Unis]

Source :

RBID : pubmed:27422298

Descripteurs français

English descriptors

Abstract

PURPOSE

The adoption of active surveillance varies widely across urological communities, which suggests a need for more consistency in the counseling of patients. To address this need we used the RAND/UCLA Appropriateness Method to develop appropriateness criteria and counseling statements for active surveillance.

MATERIALS AND METHODS

Panelists were recruited from MUSIC urology practices. Combinations of parameters thought to influence decision making were used to create and score 160 theoretical clinical scenarios for appropriateness of active surveillance. Recent rates of active surveillance among real patients across the state were assessed using the MUSIC registry.

RESULTS

Low volume Gleason 6 was deemed highly appropriate for active surveillance whereas high volume Gleason 6 and low volume Gleason 3+4 were deemed appropriate to uncertain. No scenario was deemed inappropriate or highly inappropriate. Prostate specific antigen density, race and life expectancy impacted scores for intermediate and high volume Gleason 6 and low volume Gleason 3+4. The greatest degree of score dispersion (disagreement) occurred in scenarios with long life expectancy, high volume Gleason 6 and low volume Gleason 3+4. Recent rates of active surveillance use among real patients ranged from 0% to 100% at the provider level for low or intermediate biopsy volume Gleason 6, demonstrating a clear opportunity for quality improvement.

CONCLUSIONS

By virtue of this work urologists have the opportunity to present specific recommendations from the panel to their individual patients. Community-wide efforts aimed at increasing rates of active surveillance and reducing practice and physician level variation in the choice of active surveillance vs treatment are warranted.


DOI: 10.1016/j.juro.2016.07.005
PubMed: 27422298


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Appropriateness Criteria for Active Surveillance of Prostate Cancer.</title>
<author>
<name sortKey="Cher, Michael L" sort="Cher, Michael L" uniqKey="Cher M" first="Michael L" last="Cher">Michael L. Cher</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, Wayne State University, Detroit, Michigan. Electronic address: mcher@med.wayne.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, Wayne State University, Detroit</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Dhir, Apoorv" sort="Dhir, Apoorv" uniqKey="Dhir A" first="Apoorv" last="Dhir">Apoorv Dhir</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Linsell, Susan" sort="Linsell, Susan" uniqKey="Linsell S" first="Susan" last="Linsell">Susan Linsell</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Gao, Yuqing" sort="Gao, Yuqing" uniqKey="Gao Y" first="Yuqing" last="Gao">Yuqing Gao</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Rosenberg, Bradley" sort="Rosenberg, Bradley" uniqKey="Rosenberg B" first="Bradley" last="Rosenberg">Bradley Rosenberg</name>
<affiliation wicri:level="2">
<nlm:affiliation>Comprehensive Urology, Royal Oak, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Comprehensive Urology, Royal Oak</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Jafri, S Mohammad" sort="Jafri, S Mohammad" uniqKey="Jafri S" first="S Mohammad" last="Jafri">S Mohammad Jafri</name>
<affiliation wicri:level="2">
<nlm:affiliation>Comprehensive Urology, Royal Oak, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Comprehensive Urology, Royal Oak</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Klotz, Laurence" sort="Klotz, Laurence" uniqKey="Klotz L" first="Laurence" last="Klotz">Laurence Klotz</name>
<affiliation wicri:level="4">
<nlm:affiliation>Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Ghani, Khurshid R" sort="Ghani, Khurshid R" uniqKey="Ghani K" first="Khurshid R" last="Ghani">Khurshid R. Ghani</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Bernstein, Steven J" sort="Bernstein, Steven J" uniqKey="Bernstein S" first="Steven J" last="Bernstein">Steven J. Bernstein</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Medicine, University of Michigan, Ann Arbor, Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Medicine, University of Michigan, Ann Arbor, Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Lane, Brian R" sort="Lane, Brian R" uniqKey="Lane B" first="Brian R" last="Lane">Brian R. Lane</name>
<affiliation wicri:level="2">
<nlm:affiliation>Division of Urology, Spectrum Health, Grand Rapids, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Division of Urology, Spectrum Health, Grand Rapids</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:27422298</idno>
<idno type="pmid">27422298</idno>
<idno type="doi">10.1016/j.juro.2016.07.005</idno>
<idno type="wicri:Area/Main/Corpus">000B50</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B50</idno>
<idno type="wicri:Area/Main/Curation">000B50</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B50</idno>
<idno type="wicri:Area/Main/Exploration">000B50</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Appropriateness Criteria for Active Surveillance of Prostate Cancer.</title>
<author>
<name sortKey="Cher, Michael L" sort="Cher, Michael L" uniqKey="Cher M" first="Michael L" last="Cher">Michael L. Cher</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, Wayne State University, Detroit, Michigan. Electronic address: mcher@med.wayne.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, Wayne State University, Detroit</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Dhir, Apoorv" sort="Dhir, Apoorv" uniqKey="Dhir A" first="Apoorv" last="Dhir">Apoorv Dhir</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Linsell, Susan" sort="Linsell, Susan" uniqKey="Linsell S" first="Susan" last="Linsell">Susan Linsell</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Gao, Yuqing" sort="Gao, Yuqing" uniqKey="Gao Y" first="Yuqing" last="Gao">Yuqing Gao</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Rosenberg, Bradley" sort="Rosenberg, Bradley" uniqKey="Rosenberg B" first="Bradley" last="Rosenberg">Bradley Rosenberg</name>
<affiliation wicri:level="2">
<nlm:affiliation>Comprehensive Urology, Royal Oak, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Comprehensive Urology, Royal Oak</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Jafri, S Mohammad" sort="Jafri, S Mohammad" uniqKey="Jafri S" first="S Mohammad" last="Jafri">S Mohammad Jafri</name>
<affiliation wicri:level="2">
<nlm:affiliation>Comprehensive Urology, Royal Oak, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Comprehensive Urology, Royal Oak</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Klotz, Laurence" sort="Klotz, Laurence" uniqKey="Klotz L" first="Laurence" last="Klotz">Laurence Klotz</name>
<affiliation wicri:level="4">
<nlm:affiliation>Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Ghani, Khurshid R" sort="Ghani, Khurshid R" uniqKey="Ghani K" first="Khurshid R" last="Ghani">Khurshid R. Ghani</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Bernstein, Steven J" sort="Bernstein, Steven J" uniqKey="Bernstein S" first="Steven J" last="Bernstein">Steven J. Bernstein</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Medicine, University of Michigan, Ann Arbor, Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Medicine, University of Michigan, Ann Arbor, Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name>
<affiliation wicri:level="2">
<nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Department of Urology, University of Michigan, Ann Arbor</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Lane, Brian R" sort="Lane, Brian R" uniqKey="Lane B" first="Brian R" last="Lane">Brian R. Lane</name>
<affiliation wicri:level="2">
<nlm:affiliation>Division of Urology, Spectrum Health, Grand Rapids, Michigan.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Michigan</region>
</placeName>
<wicri:cityArea>Division of Urology, Spectrum Health, Grand Rapids</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">The Journal of urology</title>
<idno type="eISSN">1527-3792</idno>
<imprint>
<date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Age Factors (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Biopsy, Needle (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunohistochemistry (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Neoplasm Grading (MeSH)</term>
<term>Neoplasm Invasiveness (pathology)</term>
<term>Prognosis (MeSH)</term>
<term>Program Evaluation (MeSH)</term>
<term>Prostate-Specific Antigen (blood)</term>
<term>Prostatic Neoplasms (mortality)</term>
<term>Prostatic Neoplasms (pathology)</term>
<term>Prostatic Neoplasms (therapy)</term>
<term>Registries (MeSH)</term>
<term>Risk Assessment (MeSH)</term>
<term>Survival Analysis (MeSH)</term>
<term>Urology (organization & administration)</term>
<term>Watchful Waiting (organization & administration)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte d'âge moyen (MeSH)</term>
<term>Analyse de survie (MeSH)</term>
<term>Antigène spécifique de la prostate (sang)</term>
<term>Appréciation des risques (MeSH)</term>
<term>Enregistrements (MeSH)</term>
<term>Facteurs âges (MeSH)</term>
<term>Grading des tumeurs (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunohistochimie (MeSH)</term>
<term>Invasion tumorale (anatomopathologie)</term>
<term>Mâle (MeSH)</term>
<term>Observation (surveillance clinique) (organisation et administration)</term>
<term>Ponction-biopsie à l'aiguille (MeSH)</term>
<term>Pronostic (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Tumeurs de la prostate (anatomopathologie)</term>
<term>Tumeurs de la prostate (mortalité)</term>
<term>Tumeurs de la prostate (thérapie)</term>
<term>Urologie (organisation et administration)</term>
<term>Évaluation de programme (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Prostate-Specific Antigen</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Invasion tumorale</term>
<term>Tumeurs de la prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en">
<term>Prostatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr">
<term>Tumeurs de la prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr">
<term>Observation (surveillance clinique)</term>
<term>Urologie</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en">
<term>Urology</term>
<term>Watchful Waiting</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Neoplasm Invasiveness</term>
<term>Prostatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Antigène spécifique de la prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Prostatic Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Tumeurs de la prostate</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Biopsy, Needle</term>
<term>Humans</term>
<term>Immunohistochemistry</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Grading</term>
<term>Prognosis</term>
<term>Program Evaluation</term>
<term>Registries</term>
<term>Risk Assessment</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Appréciation des risques</term>
<term>Enregistrements</term>
<term>Facteurs âges</term>
<term>Grading des tumeurs</term>
<term>Humains</term>
<term>Immunohistochimie</term>
<term>Mâle</term>
<term>Ponction-biopsie à l'aiguille</term>
<term>Pronostic</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Évaluation de programme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>
<b>PURPOSE</b>
</p>
<p>The adoption of active surveillance varies widely across urological communities, which suggests a need for more consistency in the counseling of patients. To address this need we used the RAND/UCLA Appropriateness Method to develop appropriateness criteria and counseling statements for active surveillance.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>MATERIALS AND METHODS</b>
</p>
<p>Panelists were recruited from MUSIC urology practices. Combinations of parameters thought to influence decision making were used to create and score 160 theoretical clinical scenarios for appropriateness of active surveillance. Recent rates of active surveillance among real patients across the state were assessed using the MUSIC registry.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>RESULTS</b>
</p>
<p>Low volume Gleason 6 was deemed highly appropriate for active surveillance whereas high volume Gleason 6 and low volume Gleason 3+4 were deemed appropriate to uncertain. No scenario was deemed inappropriate or highly inappropriate. Prostate specific antigen density, race and life expectancy impacted scores for intermediate and high volume Gleason 6 and low volume Gleason 3+4. The greatest degree of score dispersion (disagreement) occurred in scenarios with long life expectancy, high volume Gleason 6 and low volume Gleason 3+4. Recent rates of active surveillance use among real patients ranged from 0% to 100% at the provider level for low or intermediate biopsy volume Gleason 6, demonstrating a clear opportunity for quality improvement.</p>
</div>
<div type="abstract" xml:lang="en">
<p>
<b>CONCLUSIONS</b>
</p>
<p>By virtue of this work urologists have the opportunity to present specific recommendations from the panel to their individual patients. Community-wide efforts aimed at increasing rates of active surveillance and reducing practice and physician level variation in the choice of active surveillance vs treatment are warranted.</p>
</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27422298</PMID>
<DateCompleted>
<Year>2019</Year>
<Month>01</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>01</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1527-3792</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>197</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2017</Year>
<Month>01</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of urology</Title>
<ISOAbbreviation>J Urol</ISOAbbreviation>
</Journal>
<ArticleTitle>Appropriateness Criteria for Active Surveillance of Prostate Cancer.</ArticleTitle>
<Pagination>
<MedlinePgn>67-74</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0022-5347(16)30778-9</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.juro.2016.07.005</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE">The adoption of active surveillance varies widely across urological communities, which suggests a need for more consistency in the counseling of patients. To address this need we used the RAND/UCLA Appropriateness Method to develop appropriateness criteria and counseling statements for active surveillance.</AbstractText>
<AbstractText Label="MATERIALS AND METHODS">Panelists were recruited from MUSIC urology practices. Combinations of parameters thought to influence decision making were used to create and score 160 theoretical clinical scenarios for appropriateness of active surveillance. Recent rates of active surveillance among real patients across the state were assessed using the MUSIC registry.</AbstractText>
<AbstractText Label="RESULTS">Low volume Gleason 6 was deemed highly appropriate for active surveillance whereas high volume Gleason 6 and low volume Gleason 3+4 were deemed appropriate to uncertain. No scenario was deemed inappropriate or highly inappropriate. Prostate specific antigen density, race and life expectancy impacted scores for intermediate and high volume Gleason 6 and low volume Gleason 3+4. The greatest degree of score dispersion (disagreement) occurred in scenarios with long life expectancy, high volume Gleason 6 and low volume Gleason 3+4. Recent rates of active surveillance use among real patients ranged from 0% to 100% at the provider level for low or intermediate biopsy volume Gleason 6, demonstrating a clear opportunity for quality improvement.</AbstractText>
<AbstractText Label="CONCLUSIONS">By virtue of this work urologists have the opportunity to present specific recommendations from the panel to their individual patients. Community-wide efforts aimed at increasing rates of active surveillance and reducing practice and physician level variation in the choice of active surveillance vs treatment are warranted.</AbstractText>
<CopyrightInformation>Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Cher</LastName>
<ForeName>Michael L</ForeName>
<Initials>ML</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, Wayne State University, Detroit, Michigan. Electronic address: mcher@med.wayne.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dhir</LastName>
<ForeName>Apoorv</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Auffenberg</LastName>
<ForeName>Gregory B</ForeName>
<Initials>GB</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Linsell</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Gao</LastName>
<ForeName>Yuqing</ForeName>
<Initials>Y</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rosenberg</LastName>
<ForeName>Bradley</ForeName>
<Initials>B</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Urology, Royal Oak, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Jafri</LastName>
<ForeName>S Mohammad</ForeName>
<Initials>SM</Initials>
<AffiliationInfo>
<Affiliation>Comprehensive Urology, Royal Oak, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Klotz</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>David C</ForeName>
<Initials>DC</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ghani</LastName>
<ForeName>Khurshid R</ForeName>
<Initials>KR</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Bernstein</LastName>
<ForeName>Steven J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of Michigan, Ann Arbor, Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Montie</LastName>
<ForeName>James E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo>
<Affiliation>Department of Urology, University of Michigan, Ann Arbor, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lane</LastName>
<ForeName>Brian R</ForeName>
<Initials>BR</Initials>
<AffiliationInfo>
<Affiliation>Division of Urology, Spectrum Health, Grand Rapids, Michigan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<CollectiveName>Michigan Urological Surgery Improvement Collaborative</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2016</Year>
<Month>07</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Urol</MedlineTA>
<NlmUniqueID>0376374</NlmUniqueID>
<ISSNLinking>0022-5347</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 3.4.21.77</RegistryNumber>
<NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Urol. 2016 Oct 31;13(11):633-634</RefSource>
<PMID Version="1">27797361</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001707" MajorTopicYN="N">Biopsy, Needle</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014572" MajorTopicYN="N">Urology</DescriptorName>
<QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D057832" MajorTopicYN="N">Watchful Waiting</DescriptorName>
<QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="Y">counseling</Keyword>
<Keyword MajorTopicYN="Y">decision making</Keyword>
<Keyword MajorTopicYN="Y">program evaluation</Keyword>
<Keyword MajorTopicYN="Y">prostatic neoplasms</Keyword>
<Keyword MajorTopicYN="Y">watchful waiting</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="accepted">
<Year>2016</Year>
<Month>07</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>7</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2019</Year>
<Month>1</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>7</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27422298</ArticleId>
<ArticleId IdType="pii">S0022-5347(16)30778-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.juro.2016.07.005</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Canada</li>
<li>États-Unis</li>
</country>
<region>
<li>Michigan</li>
<li>Ontario</li>
</region>
<settlement>
<li>Toronto</li>
</settlement>
<orgName>
<li>Université de Toronto</li>
</orgName>
</list>
<tree>
<country name="États-Unis">
<region name="Michigan">
<name sortKey="Cher, Michael L" sort="Cher, Michael L" uniqKey="Cher M" first="Michael L" last="Cher">Michael L. Cher</name>
</region>
<name sortKey="Auffenberg, Gregory B" sort="Auffenberg, Gregory B" uniqKey="Auffenberg G" first="Gregory B" last="Auffenberg">Gregory B. Auffenberg</name>
<name sortKey="Bernstein, Steven J" sort="Bernstein, Steven J" uniqKey="Bernstein S" first="Steven J" last="Bernstein">Steven J. Bernstein</name>
<name sortKey="Dhir, Apoorv" sort="Dhir, Apoorv" uniqKey="Dhir A" first="Apoorv" last="Dhir">Apoorv Dhir</name>
<name sortKey="Gao, Yuqing" sort="Gao, Yuqing" uniqKey="Gao Y" first="Yuqing" last="Gao">Yuqing Gao</name>
<name sortKey="Ghani, Khurshid R" sort="Ghani, Khurshid R" uniqKey="Ghani K" first="Khurshid R" last="Ghani">Khurshid R. Ghani</name>
<name sortKey="Jafri, S Mohammad" sort="Jafri, S Mohammad" uniqKey="Jafri S" first="S Mohammad" last="Jafri">S Mohammad Jafri</name>
<name sortKey="Lane, Brian R" sort="Lane, Brian R" uniqKey="Lane B" first="Brian R" last="Lane">Brian R. Lane</name>
<name sortKey="Linsell, Susan" sort="Linsell, Susan" uniqKey="Linsell S" first="Susan" last="Linsell">Susan Linsell</name>
<name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name>
<name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name>
<name sortKey="Rosenberg, Bradley" sort="Rosenberg, Bradley" uniqKey="Rosenberg B" first="Bradley" last="Rosenberg">Bradley Rosenberg</name>
</country>
<country name="Canada">
<region name="Ontario">
<name sortKey="Klotz, Laurence" sort="Klotz, Laurence" uniqKey="Klotz L" first="Laurence" last="Klotz">Laurence Klotz</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteMusiqueV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A83 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SanteMusiqueV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27422298
   |texte=   Appropriateness Criteria for Active Surveillance of Prostate Cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27422298" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SanteMusiqueV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 8 15:23:44 2021. Site generation: Mon Mar 8 15:23:58 2021